Brusatol, an NRF2 inhibitor, induced the apoptosis of non‐small cell lung cancer cells [217], hindered the progression of bladder cancer cells [218], attenuated the proliferation and invasion of differentiated thyroid cancer cells [219], improved the vulnerability of pancreatic cancer to chemotherapy [220], and sensitized endometrial hyperplasia and cancer to progestin [221]. Here, NFE2L2 is linked to cancer.